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Disorders of sex development (DSD) are conditions where genetic, gonadal, and/or
internal/external genital sexes are discordant. In many cases, serum testosterone
determination is insufficient for the differential diagnosis. Anti-Müllerian hormone (AMH),
a glycoprotein hormone produced in large amounts by immature testicular Sertoli cells,
may be an extremely helpful parameter. In undervirilized 46,XY DSD, AMH is low in
gonadal dysgenesis while it is normal or high in androgen insensitivity and androgen
synthesis defects. Virilization of a 46,XX newborn indicates androgen action during fetal
development, either from testicular tissue or from the adrenals or placenta. Recognizing
congenital adrenal hyperplasia is usually quite easy, but other conditions may be more
difficult to identify. In 46,XX newborns, serum AMH measurement can easily detect
the existence of testicular tissue, leading to the diagnosis of ovotesticular DSD. In sex
chromosomal DSD, where the gonads are more or less dysgenetic, AMH levels are
indicative of the amount of functioning testicular tissue. Finally, in boys with a persistent
Müllerian duct syndrome, undetectable or very low serum AMH suggests a mutation of
the AMHgene, whereas normal AMH levels orient toward amutation of the AMH receptor.
Keywords: testis, ovary, Turner syndrome, Klinefelter syndrome, persistent Müllerian duct syndrome, gonadal
dysgenesis, Sertoli cell, Leydig cell
INTRODUCTION
DSD can be defined as conditions where genetic, gonadal, and/or internal/external genital sex are
discordant. The most common cause of DSD, congenital adrenal hyperplasia (CAH), is easily
recognized, but other conditions may be more difficult to diagnose. Anti-Müllerian hormone
(AMH), produced in large amounts exclusively by the fetal and prepubertal testis, is an important
parameter for differential diagnosis, particularly in children. AMH plays a key role in male
sex differentiation.
DIFFERENTIATION OF THE GENITAL TRACT
Initially, the internal reproductive tract is identical in XX and XY embryos. Mesonephric (Wolffian)
ducts form in the intermediate mesoderm during the 4th week and elongate caudally in direction
of the urogenital sinus (1). During the 5th week, coelomic cells specified to become Müllerian cells
form a cleft between the gonadal and mesonephric ridges, laterally to the Wolffian ducts. Then,
these cells invaginate caudally until they reach the Wolffian duct, a step requiring the expression
of WNT4 by the mesonephric mesenchyme (2). The Müllerian ducts grow toward the urogenital
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sinus, crossing the Wolffian ducts ventrally, thus finally lying
medially and fusing to give rise to the uterovaginal canal in
the midline (3). Elongation of the Müllerian duct is regulated
by WNT9B secreted by the Wolffian duct epithelium (4) and
requires physical contact with the latter (3).
The subsequent fate of the Müllerian duct differs markedly
according to sex. In the normal male, its cranial end shows signs
of impending regression even before the Müllerian duct reaches
the urogenital sinus, coinciding with the beginning of secretion
of AMH by Sertoli cells. The Müllerian duct morphologically
resembles an epithelial tube but expresses mesenchymal cell
markers. These mesoepithelial characteristics persist during
regression while, at the same age, the female Müllerian duct
becomes exclusively epithelial, heralding the end of the window
of sensitivity to AMH (5). Müllerian regression is characterized
by loss of the epithelial basement membrane and by apoptosis,
progressing toward the urogenital sinus. In the human fetus at 9
weeks, Müllerian ducts have nearly totally disappeared.
Leydig cells, under the effect of placental human chorionic
gonadotropin (hCG), produce testosterone, which acts directly
on the Wolffian ducts promoting their differentiation into
epididymides, vasa deferentia, and seminal vesicles by the 12th
week. Male differentiation of the genitalia, including fusion of
the labioscrotal folds to form the scrotum, closure of the urethral
folds, and positioning of the meatus at the tip of the phallus, is
completed by the end of the first trimester of fetal life. The genital
tubercle forms the corpora cavernosa and corpus spongiosum
of the penis. In the second half of gestation, fetal pituitary
LH takes over the regulation of testosterone production, which
drives the increase in penile size and—together with the Leydig
cell factor insulin-like 3 (INSL3)—the descent of the testes to
scrotal position.
In the absence of testicular hormones, whether ovaries are
present or not and irrespective of karyotype, differentiation of
the genital tract follows the female pathway. In the absence of
AMH, the Müllerian ducts form the Fallopian tube, the uterus,
and the upper part of the vagina. They become resistant to AMH
when they lose their mesenchymal markers to become purely
epithelial (5). In the absence of androgen action, Wolffian ducts
regress through an active process induced by COUP-TF2 (6). The
prostate does not differentiate, and the vagina opens separately
from the urethra on the surface of the perineum. The urethral
folds do not fuse and give rise to the labia minora; the labioscrotal
swellings also remain separated to form the labia majora. The
genital tubercle does not grow and forms the clitoris. For a
detailed description of sex differentiation, see ref. (7).
AMH, A MEMBER OF THE TGF-BETA
FAMILY
AMH, a member of the transforming growth factor beta (TGFβ)
family (8) secreted by Sertoli cells immediately after testicular
differentiation, is responsible for the regression of Müllerian
ducts in the male fetus. Like other members of the TGFβ family,
AMH is translated as a dimeric precursor protein comprising
two polypeptide chains, each containing a large N-terminal
pro-region and a much smaller C-terminal mature domain
homologous to those of the other members of the TGFβ family.
Proteolytic cleavage at arginine 451 yields 110-kDa N-terminal
and 25-kDa C-terminal dimers which remain associated in a
bioactive non-covalent complex (9). The human AMH gene
(8), only 2.8 kb long and located on chromosome 19p13.3 (10),
contains five exons; the 3
′
end of the fifth exon encodes the
bioactive C-terminal domain. GATA, SF1, and SOX9 binding
sites present within 418 bp of the translation start site activate
AMH expression; sites further upstream are required for normal
regulation (11).
Like othermembers of the TGFβ family, AMH signals through
two membrane-bound serine/threonine kinase receptors and
several cytoplasmic R-SMAD effectors. The primary receptor,
AMHR2 gene contains 11 exons spread over 8 kbp and maps
to chromosome 12q13.13 (12). After binding of AMHR2 to its
specific ligand AMH, the complex recruits a type I receptor,
either the BMP receptors BMPR1A, aka ALK3, or BMPR1B, aka
ALK6, or the activin receptor ACVR1, aka ALK2, resulting in the
phosphorylation of SMADS 1, 5, or 8. The type I receptor and
SMAD repertoire is shared with the bone morphogenetic protein
family, AMH’s closest relatives within the TGFβ family (7).
Tight regulation of AMH transcription is crucial for
regression of Müllerian ducts since they are able to respond to
AMH only within a very narrow time window (13). Surprisingly,
however, production does not cease once Müllerian ducts have
disappeared; it continues up to puberty. Initially, transcription
requires the cooperation of various transcription factors, SOX9,
SF1, GATA4, and WT1, to name only a few [reviewed in (14)].
Later in fetal life and after birth, testicular AMH production is
increased by FSH signaling through its seven-transmembrane
receptor and the pathway involving the Gsα subunit (15), cyclic
AMP, protein kinase A, and transcription factors SOX9, SF1,
AP2, and NFκB (11) (Figure 1). Transcription is downregulated
by androgens (16). Testosterone acts through the androgen
receptor and requires intact binding sites for SF1 on the AMH
promoter (17) (Figure 2).
WHY MEASURE AMH IN DSD?
Müllerian ducts have completely disappeared in the male 10
weeks after conception, but testes continue to churn out high
amounts of AMH throughout childhood, when basal testosterone
and gonadotropin levels have little clinical use. It is precisely
the fact that AMH continues to be secreted at high levels by
Sertoli cells during infancy and childhood, when it has no longer
a physiological action on Müllerian ducts, which makes AMH
such an appealing biomarker for pediatric endocrinologists, not
to mention that prior gonadotropin stimulation is not required.
In theory, to determine whether AMH has been secreted or not
in a DSD patient, a look at Müllerian derivatives by laparoscopy
or sonography should suffice. However, laparoscopy is invasive,
and sonography is not always reliable in newborns. Measurement
of AMH concentration in serum by ELISA has been available
since 1990 and is now offered by multiple companies (please
refer to another article devoted to AMH assays in the same
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FIGURE 1 | Upregulation of AMH production in testicular Sertoli cells. Left: onset of AMH expression in early fetal life is independent of gonadotropins and depends
on transcription factors SOX9, which triggers AMH expression, and SF1, GATA4, and WT1, which further increase AMH transcription by binding to specific response
elements on the proximal AMH promoter. Right: increase of testicular AMH production in response to FSH, involving the FSH receptor-Gsα protein-adenylate cyclase
(AC)-cyclic AMP (cAMP) pathway, which activates protein kinase A (PKA)-mediated induction of SOX9, SF1, NFκB, and AP2. These factors bind to their specific
response elements on the AMH promoter. Reproduced with permission from ref. (11). Copyright© 2011 the American Physiological Society and © 2020 MDText.com,
Inc.
series). However, the information provided by imaging andAMH
measurement is not similar. The state of theMüllerian derivatives
reflects the effect of AMH secreted very early in fetal life, while
serum AMH reflects the amount secreted at the time blood is
drawn, and the two do not necessarily coincide (18).
The concentration of AMH, one of the first proteins produced
by the fetal testis, is high in serum during fetal life though not
detectable in amniotic fluid (19). Although it declines transiently
at birth, it remains distinctly higher in males than in females
and increases again during the 1st month (20) to reach its peak
in the 2nd year of life (21, 22). Circulating levels remain high
during childhood but fall at the onset of puberty, downregulated
by the rising intratesticular concentration of testosterone. The
normal AMH serum concentration in developing boys is shown
in Figure 3. Interestingly, during the fetal period and early
infancy, Sertoli cells do not express the androgen receptor and are
thus insensitive to the high levels of testosterone of minipuberty
(23–25) and references therein.
What does AMH tell us in DSD? Serum concentrations clearly
above female values indicate that testicular tissue is present.
Testicular tissue virilizes the fetus through the combined action
of two hormones, AMH and testosterone. If both are defective,
global testicular dysgenesis is probably involved. If only one is
deficient, a block in the synthesis or action of either testosterone
or AMH is likely. Serum AMH is also a reliable biomarker of
the balance between FSH and androgen action within the testis
(26): high AMH indicates FSH stimulation and lack of androgen
action as in androgen insensitivity whereas low AMH suggests
a predominant androgen inhibiting action, as in precocious
puberty. Furthermore, in prepubertal DSD patients, serum AMH
measurement monitors Sertoli cell function, a very useful feature
since testicular tissue tends to deteriorate over time in DSD.
In the ovary, low amounts of AMH are produced by the
granulosa cells of primary and small antral follicles (27–29),
starting from the 25th week of fetal life (30). At that time,
Müllerian derivatives are no longer sensitive to AMH (5, 31).
Serum AMH is 50-fold lower in girls than in boys at birth (20)
and remains relatively stable from childhood through young
adulthood (32).
THE 46,XY CHILD WITH DSD
According to the original DSD consensus statement (33) updated
in 2016 (34), DSD are initially classified according to the
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FIGURE 2 | Downregulation of AMH production in testicular Sertoli cells by androgens. In the absence of androgens (e.g., normal childhood and DSD with impaired
androgen production) or androgen receptor (AR, e.g., normal fetal and neonatal periods and DSD due to androgen insensitivity syndromes), SF1 binds to its response
elements on the AMH promoter and increases AMH transcription. When androgen action on the AR is effective in the Sertoli cell (e.g., at puberty), the ligand-activated
AR could either block SF1 binding to the AMH promoter (blockage by competition) or interact with site-bound-SF1 and prevent it from exerting its stimulatory effect on
AMH promoter (blockage by interaction). Modified with permission from (17). Copyright © The Author(s) 2018.
FIGURE 3 | Serum AMH levels in normal males. The dotted lines represent the 97, 50, and 3rd percentiles. To obtain serum AMH in ng/mL, divide by 7.14.
Reproduced with permission from ref. (22). Copyright © The Author(s) 2011.
Frontiers in Endocrinology | www.frontiersin.org 4 September 2020 | Volume 11 | Article 619
Josso and Rey AMH in DSD
TABLE 1 | Classification of disorders of sex development (DSD) according to the karyotype and the underlying pathogenesis.
Affected process 46,XY 46,XX Chromosomal






differentiation (or mixed gonadal
dysgenesis)
Ovotesticular DSD
Klinefelter and Turner syndromes




Exposure to maternal androgenic
tumors or drugs
None
Androgen action (isolated) CAIS / PAIS None None
AMH production or action
(isolated)
PMDS None None
CAIS, Complete androgen insensitivity syndrome; PAIS, Partial androgen insensitivity syndrome; PMDS, persistent Müllerian duct syndrome.
patient’s karyotype into 46,XY, 46,XX, and sex-chromosome DSD
(Table 1). Incomplete or total lack of virilization of the external
genitalia in 46,XY individuals may result from insufficient
testosterone production by the gonads or defective androgen
action at the target organ level. If the deficiency is complete,
genitalia have a normal female appearance at birth (Figure 4),
and the condition may go undiagnosed until puberty, unless
a karyotype is performed for other reasons, before or after
birth. Partial defects result in genital ambiguity leading to earlier
medical intervention.
Combined AMH and Testosterone
Insufficiency: A Hallmark of Gonadal
Dysgenesis
Testosterone, a steroid responsible for genital virilization, and
AMH, a glycoprotein member of the TGFβ family, are entirely
different molecules with specific biosynthetic and signaling
pathways. A defect in both implies that the entire testis is
abnormal. In the most extreme scenario, genitalia are completely
female and Müllerian derivatives; uterus and Fallopian tubes are
normal, suggesting that testes have never existed or functioned in
the first place (Figure 4D). Serum AMH is undetectable (35, 36)
(i.e., even lower than in 46,XX girls). This condition, known as
pure (or complete) gonadal dysgenesis or Swyer syndrome, is
the complete form of early fetal-onset primary gonadal failure
(37, 38) and is sometimes labeled “sex reversal” although gonads
are represented by streaks, not ovaries.
Primary Gonadal Failure May Be Partial
The external genitalia are partially virilized, resulting in
micropenis and hypospadias or clitoral hypertrophy and labial
fusion in a female perspective. Ultrasound examination usually
reveals the presence of more or less developed Müllerian
derivatives (Figure 4E). The serum AMH concentration is lower
than in boys of similar age. Testosterone response to hCG is also
blunted, but this in itself does not rule out the possibility of an
isolated defect in Leydig cell steroidogenesis or a mutation in
the LH/CG receptor. However, in the latter conditions, AMH is
produced normally, there are noMüllerian derivatives, and AMH
concentration is normal for age and sex. A frequent variant of
partial gonadal failure is represented by mixed or asymmetrical
gonadal dysgenesis (39), characterized by the presence of a
testis on one side and a streak gonad on the other (40). These
patients often exhibit congenital malformations evocative of
Turner syndrome, and their karyotype is typically 45,X/46,XY.
Müllerian derivatives are often absent on the testicular side.
Familial cases of complete or incomplete gonadal dysgenesis
are frequent. Molecular defects affecting the testis determination
pathway (41) are often detected. In contrast to autosomal
recessive steroidogenic defects, gene haploinsufficiency is often
sufficient to disrupt testicular differentiation.
All patients with XY gonadal dysgenesis are at risk for
malignant germ cell tumors and should be closely monitored
(42). In itself, presence of Müllerian remnants should alert the
clinician to this possibility. Formerly, cancer risk was a decisive
argument for choosing a female sex of rearing in poorly virilized
patients with Müllerian organs, because the decision involved
early bilateral gonadectomy. Today, some human rights activists
consider that genitoplasty of infants should be outlawed [see (43–
45)], with the result that dysgenetic testes may be left in situ until
the child reaches prepuberty (46), a particularly dangerous age
for the onset of germ cell malignancy (47).
Isolated Testosterone Insufficiency:
Steroidogenesis Defect or Testosterone
Insensitivity?
AMH is also helpful if an androgen synthesis or action defect is
suspected in a patient with DSD. Indeed, ambiguous or female
genitalia are indicative of androgen failure, but testosterone
levels cannot distinguish between gonadal dysgenesis and specific
Leydig cell disorders or androgen insensitivity during childhood.
Serum AMH can orient the diagnosis: it is low or undetectable
in gonadal dysgenesis, but normal or high in isolated Leydig cell
disorders or androgen insensitivity.
Testosterone Synthesis Defects
The initial steps of steroidogenesis are shared by the adrenals
and the gonads; thus, defects of testosterone synthesis are often
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FIGURE 4 | (A) Undifferentiated stage of fetal sex development. (B) Male differentiation in normal 46,XY individuals and patients with 46,XX testicular DSD or
Klinefelter syndrome. (C) Female external genitalia in patients with 46,XY DSD due to impaired androgen synthesis or action. (D) Female genital differentiation in
normal 46,XX individuals and patients with dysgenetic DSD associated with 46,XX, 45,X or 46,XY genotypes. (E) Ambiguous external genitalia in patients with
testicular or ovotesticular dysgenesis with different karyotypes. (F) Ambiguous external genitalia in patients with 46,XY DSD due to impaired androgen synthesis or
action. (G) Male external genitalia and persistence of Müllerian ducts in 46,XY patients with AMH or AMHR2 gene defects.
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associated with rare forms of congenital adrenal hyperplasia
(48) (Figure 5). Briefly, cholesterol is transferred to the
inner mitochondrial membrane by the steroidogenic acute
regulatory protein (StAR) in response to LH or hCG and
then converted to pregnenolone by the cytochrome P450
side chain cleavage (P450scc), an enzyme located at the inner
mitochondrial membrane. 3ß-Hydroxysteroid dehydrogenase
(3ß-HSD) and ultimately 17β-hydroxysteroid dehydrogenase
(17ß-HSD) sequentially synthesize testosterone from the
pregnenolone precursor. P450 oxido-reductase (POR) serves
as an electron donor for all microsomal cytochrome P450
enzymes (50). Mutations in any of these enzymes or in the
LH/CG receptor curtail hCG-stimulated testosterone production
to levels observed in patients with gonadal dysgenesis (51).
However, the level of serum AMH is normal or elevated and
no Müllerian derivatives are detectable, allowing to make the
distinction (Figure 4C). The identification of the defective
enzyme requires the assay of steroid hormone precursors prior
to Sanger sequencing of the suspect gene unless massive parallel
sequencing targeted to DSD genes is chosen as a shortcut. All
steroidogenic defects are transmitted as recessive autosomal
traits, including those that affect testosterone metabolism.
Dihydrotestosterone Synthesis Defects
Testosterone can be converted to its more potent metabolite
DHT by the enzyme 5α-reductase type 2 (52) expressed in
androgen target organs such as fetal genital skin, male accessory
sex glands, and prostate. Mutations in the SR25A2 gene are
the most frequent cause (53, 54). Alternatively, DHT can be
synthesized through the “backdoor” pathway without going
through a testosterone intermediate (55). Defects in DHT
production lead to very poor virilization of target organs, and
most patients are considered girls at birth. Serum testosterone is
unremarkable; the T/DHT ratio is high, after hCG stimulation
if necessary. The AMH level is in the lower range of normal
(56), indicating that testosterone does not need to be metabolized
to DHT to regulate AMH production by the Sertoli cell. From
a practical viewpoint, it is very important to distinguish 5α-
reductase deficiency from other types of XYDSDbecause if raised
as girls, patients often switch to a male sex at puberty, an unusual
occurrence in androgen insensitivity.
Androgen insensitivity is the consequence of a mutation
in the androgen receptor that is coded by a gene on the X
chromosome; transmission is recessive sex-linked, affecting only
males who lack a normal X chromosome. Again, the condition
can be complete (CAIS), characterized by an external female
phenotype or partial (PAIS), leading to ambiguous genitalia.
In both instances, Müllerian ducts are normally regressed
(Figure 4C). The level of serum AMH depends on the age of the
patient. During the 1st year of life and at puberty, AMH levels
are extremely high, reflecting the stimulation of AMH by FSH
unimpeded by testosterone action (57). Serum testosterone is
also elevated. Pubertal maturation is female in CAIS, except that
menstruation cannot occur. In children, at present, molecular
analysis of the androgen receptor is the diagnostic method of
choice since testosterone and gonadotropin levels overlap for
PAIS, 5α-reductase type 2 deficiency and steroidogenic defects.
In summary, in undervirilized XY DSD, low AMH is typical
of gonadal dysgenesis (1 and 3 in Figure 6) while normal to
high levels are observed in androgen insensitivity and androgen
synthesis defects (2 and 4 in Figure 6). In most other forms
of XY DSD linked to testosterone insufficiency, the AMH
serum level is normal for age and diagnosis rests essentially
on the assay of testosterone and its precursors as well as
metabolites and gonadotropins. However, biochemical results are
not always clear-cut, and today, molecular analysis is assuming
an increasingly important role. Targeted or whole exome new-
generation sequencing has significantly improved the proportion
of diagnosed XY DSD cases (58, 59).
The Male Child With Impalpable Testes
At first glance, a newborn boy with impalpable testes is not a DSD
candidate, unless his karyotype dictates otherwise. Once a 46,XY
karyotype has been ascertained, the pediatrician must choose
between two possibilities: bilateral cryptorchidism or anorchia.
AMH is very helpful in this regard if its level is higher than the
normal female value, testicular tissue must exist (60, 61) because
the prepubertal testis is the only organ capable of secreting large
amounts of AMH.
Cryptorchidism is frequently observed in newborns,
particularly in preterm ones. To test for the presence of testicular
tissue, basal testosterone assay and gonadotropin measurement
may not be informative, depending on age. In contrast, an
AMH level above female values establishes without a doubt that
testicular tissue is present and is an indication for surgery if the
testes do not descend spontaneously within the first 6 months
of life. AMH is moderately decreased in cryptorchidism; even
unilateral but still much higher than in females (62), an hCG test
is not required.
In patients with impalpable testes, anorchia, although rare,
is a possibility that should be considered. Since the external
and internal phenotype is unequivocally male, it is obvious
that testes were present at least up to month 4 of fetal life
and disappeared after fetal sex differentiation was completed.
Indeed, in some instances, testes were palpable at birth and
vanished later. The condition is apparently due to degeneration
subsequent to testicular torsion, and no genetic alterations were
detected in 26 cases (63). AMH is not detectable in serum;
however, ultrasound examination should be performed to rule
out persistent Müllerian duct syndrome (PMDS) due to an AMH
mutation. Testosterone and gonadotropin assays are also helpful
in this regard.
Isolated AMH Insufficiency: The Persistent
Müllerian Duct Syndrome
Most types of DSD are characterized by testosterone dysfunction,
isolated or not. The persistent Müllerian duct syndrome (PMDS)
is the only example of DSD due to an isolated defect of AMH
synthesis or action (Figure 4G). PMDS is a rare autosomal
recessive disorder characterized by the persistence of Müllerian
derivatives, uterus, and Fallopian tubes, in otherwise completely
virilized 46,XY males. Bilateral cryptorchidism is observed most
frequently: the uterus remains anchored to the pelvis and
mechanically prevents testicular descent because it is tethered
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FIGURE 5 | Steroidogenesis steps in testicular Leydig cells (within the dotted blue box) and in the adrenals, ovaries, and placenta (outside the box). Reproduced with
permission from (49). Copyright© 2020 Grinspon, Bergadá and Rey.
to the testes by the male excretory ducts. Alternatively, one or
both testes may make it into the inguinal canal or the scrotum,
dragging the uterus along. This may result either in unilateral
cryptorchidism with a hernia containing the uterus on the
opposite side, a condition known as “hernia uteri inguinalis.”
The testis on the opposite side can be drawn into the same
hemiscrotum by gentle traction or may already be present there;
this condition typical of PMDS is named “transverse testicular
ectopia.” The anatomical picturemay vary within the same family
and is not correlated with the genotype (64).
The condition is due to mutations of either the AMH or
AMHR2 gene (65). Molecular diagnosis has now been achieved
in nearly 200 patients worldwide. Serum AMH is usually very
low or undetectable in mutations of the AMH gene, even those
affecting the inactive N-terminal proregion. In contrast, the
AMH serum level does not significantly differ from control
values in mutations of AMHR2 or in idiopathic cases, in which
no genetic abnormality of either AMH or AMHR2 has been
detected, but this is becoming rarer as new-generation massive
parallel sequencing is gaining ground.
In practice, diagnosis of PMDS poses few problems in
familial cases or in patients with hernia uteri inguinalis or
transverse testicular ectopia, both very evocative. In patients
with impalpable testes, other disorders must be ruled out such
as simple bilateral cryptorchidism, anorchia, or even Prader V
congenital adrenal hyperplasia, assuming karyotype analysis has
not been performed. Paradoxically, in this regard, AMH assay
is of little value because according to the gene involved, serum
AMH can be either undetectable as in anorchia and CAH or
normal or in the lower range of normal, as in cryptorchidism.
Ultrasound pelvic examination to display Müllerian organs is the
diagnostic method of choice. AMH assay is useful only to orient
molecular investigation.
THE 46,XX CHILD WITH DSD
Complete or partial virilization of an XX individual is due to
the production of androgen, either from testicular tissue or from
other sources: the fetal adrenal, the placenta, or very rarely an
ovarian tumor in the mother. Adrenals, placenta, and ovaries do
not synthesize AMH, at least not in significant amounts. Thus,
AMH assay can easily detect the presence of testicular tissue in
such patients.
46,XX DSD With Testicular Tissue
Testes are not expected to differentiate in the absence of a
Y chromosome, with possible exceptions. SRY may translocate
from the Y to X chromosome during paternal meiosis (66, 67),
an XY cell line may lurk in gonadal tissue, or a mutation or
copy number variations in critical genes may upset the fragile
equilibrium between protestis and proovary genetic pathways
[reviewed in (68)]. Serum AMH above the low levels expected
for a female sound the alert if the phenotype is ambiguous
(Figure 4E).
XX males are endowed with bilateral testes and are usually
fully virilized (Figure 4B); in most, but not all cases, Y material
can be detected in their DNA, usually located on an X
chromosome, but a minority of XX males are SRY negative
and often sexually ambiguous. XX males resemble Klinefelter
boys insofar as childhood is usually uneventful, XX germ cell
degeneration sets in at puberty, and infertility is inevitable. AMH
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FIGURE 6 | Schematic of AMH levels in various types of disorders of sex development (DSD) in relationship to the aspect of the external genitalia and age. The
shaded area represents reference levels for AMH, as obtained from ref. (22).
is in the normal range during childhood and falls subsequently (6
in Figure 6).
Ovotesticular DSD is a multifaceted condition defined by
the coexistence in the same individual of testicular and ovarian
tissue, either separate or associated within an ovotestis. External
genitalia can be more or less virilized, but internally, a uterus
is present in 70% of cases (69) and ovarian tissue is functional
whereas testicular tissue is usually dysgenetic. An AMH serum
level above normal female values in a sexually ambiguous XX
baby is a strong argument for the diagnosis (7 in Figure 6). Values
approaching male standards are found only during the first 2
weeks after birth in patients with large amounts of testicular
tissue (35); later, AMH concentration decreases in keeping
with the progressive degeneration of testicular tissue (69). Most
karyotypes are 46,XX or 46,XX/46,XY chimerisms (Figure 4E).
A 45,X/46,XY mosaic should awaken suspicion of mixed or
asymmetrical gonadal dysgenesis, in case an undifferentiated
streak with “ovarian stroma” has been mistaken for genuine
ovarian tissue (70).
46,XX DSD Without Testicular Tissue
In this context, the androgens responsible for virilization of the
external genitalia come from an extra-testicular, source but in
the absence of Sertoli cells, AMH is not produced. Congenital
adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency
accounts for more than half the cases of DSD and is the first
diagnosis evoked by a pediatrician confronted with a sexually
ambiguous or apparently male baby with impalpable testes.
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Aromatase deficiency, a rare condition due to a mutation in
placental cP450arom (71), should only be considered in an
XX sexually ambiguous child once CAH has been ruled out,
and AMH is in the female range, thus ruling out ovotesticular
DSD. Maternal ovarian tumors, for instance hCG-dependent
luteomas, are another rare cause of XX DSD (72). Exogenous
androgen or progestin administration during pregnancy, as a
cause of fetal virilization, is extremely rare nowadays (73). In all
these conditions, AMH serum values are in the female range (5
in Figure 6), uterus, Fallopian tubes, and ovaries are normal.
SEX CHROMOSOMAL DSD
Sex chromosomal DSD designate conditions where sex
chromosomes are neither uniformly XX nor XY. Mosaicisms
or chimeras with at least one Y-chromosome lineage are
usually associated with DSD due to mixed or asymmetrical or
ovotesticular dysgenesis. The AMH level in serum is grossly
correlated with the amount of functioning testicular tissue
present (35).
Turner Syndrome
Women with Turner syndrome have different karyotypes, all
of which lack X chromosomal material; a 45,X karyotype is
present in 40–50% of cases, 45,X/46,XX in 15–25% (74). Patients
experience accelerated loss of ovarian follicles starting in fetal
life and inexorably leading to ovarian insufficiency and infertility
at various ages (75, 76). Preservation of fertility may be feasible
by cryopreservation of ovarian tissue before follicles have totally
vanished. AMH assay, often considered a marker of ovarian
reserve, is detectable in a fifth of Turner girls (8 in Figure 6),
essentially those with a mosaic 46,XX cell line, indicating
that follicles are still present and cryopreservation is still a
viable option.
Klinefelter Syndrome
Klinefelter syndrome is the most common form of
hypogonadism in males. It is characterized by a supernumerary
X chromosome; the classical 47,XXY karyotype is present in
90% of cases. Cryptorchidism and mild developmental disorders
may alert to the diagnosis in childhood, but usually patients
are referred in adulthood for infertility (77). During childhood,
AMH serum level is in the normal range during childhood,
decreasing to lower levels after puberty (78, 79), indicating that
Sertoli cell function is not impaired before mid to late puberty (6
in Figure 6).
CONCLUDING REMARKS
AMH is a reliable biomarker of testicular and ovarian function
and is extremely useful for the differential diagnosis of DSD
(Figure 6), especially when confronted with serum testosterone
concentration. Sertoli cells of the testes produce high amounts
of AMH from early fetal life until the onset of puberty, while
granulosa cells of the primary and small antral ovarian follicles
produce small amounts of AMH from late fetal life until
menopause. In patients with DSD, serum AMH is useful for
the following purposes: (a) detect the existence of testicular
tissue; (b) determine the amount of functional Sertoli cells;
(c) distinguish between congenital disorders affecting whole
testicular differentiation (gonadal dysgenesis) and those affecting
exclusively Leydig cells or Sertoli cells; (d) direct the diagnosis of
PMDS to the study of the AMH or the AMHR2 gene; (e) detect
the existence of ovarian follicles and the possibility or preserving
fertility in girls with Turner syndrome; and (f) assess Sertoli cell
function in boys with Klinefelter syndrome.
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